Sp1200
NEXT GENERATION SCREENING FOR COLORECTAL CANCER--STOOL BASED TESTS, AI INFORMED COLONOSCOPY, ETC
Date
May 9, 2023
Explore related products in the following collection:
Tracks
Related Products
COLONOSCOPY ADHERENCE IN A MULTI-CENTER STUDY OF COLORECTAL CANCER (CRC) SCREENING
BACKGROUND: The Nordic-European Initiative on Colorectal Cancer (NordICC) Study highlighted the impact of adherence on the effectiveness of colonoscopy at reducing CRC incidence and mortality…
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
HABITUAL MEAT INTAKE IS ASSOCIATED WITH INCREASED RISK OF DISEASE FLARE IN ULCERATIVE COLITIS: INITIAL RESULTS FROM THE PREDICCT STUDY
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
PANEL DISCUSSION
Talks on the blood based screening test clinical trial results that will occur in 2022 and 2023 (ECLIPSE, PREEMPT, BLUE-C) and effects on clinical care; updates on multi-cancer early detection test; emerging screening tests (Oncoguard, Colonosight, etc)…